Literature DB >> 18242982

Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.

Gregory R Ott1, Naoyuki Asakawa, Zhonghui Lu, Rajan Anand, Rui-Qin Liu, Maryanne B Covington, Krishna Vaddi, Mingxin Qian, Robert C Newton, David D Christ, James M Trzaskos, James J-W Duan.   

Abstract

Novel ((2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamides were found to be excellent P1' substituents in conjunction with unique constrained beta-amino hydroxamic acid scaffolds for the discovery of potent selective inhibitors of TNF-alpha Converting Enzyme (TACE). Optimized examples proved potent for TACE, exceptionally selective over a wide panel of MMP and ADAM proteases, potent in the suppression of LPS-induced TNF-alpha in human whole blood and orally bioavailable.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18242982     DOI: 10.1016/j.bmcl.2008.01.075

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

1.  Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors.

Authors:  Prashant Revan Murumkar; Vishal Prakash Zambre; Mange Ram Yadav
Journal:  J Comput Aided Mol Des       Date:  2010-02-24       Impact factor: 3.686

Review 2.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

3.  Different signaling pathways stimulate a disintegrin and metalloprotease-17 (ADAM17) in neutrophils during apoptosis and activation.

Authors:  Yue Wang; John D Robertson; Bruce Walcheck
Journal:  J Biol Chem       Date:  2011-09-23       Impact factor: 5.157

4.  ALCAM/CD166 is a TGF-β-responsive marker and functional regulator of prostate cancer metastasis to bone.

Authors:  Amanda G Hansen; Shanna A Arnold; Ming Jiang; Trenis D Palmer; Tatiana Ketova; Alyssa Merkel; Michael Pickup; Susan Samaras; Yu Shyr; Harold L Moses; Simon W Hayward; Julie A Sterling; Andries Zijlstra
Journal:  Cancer Res       Date:  2014-01-02       Impact factor: 12.701

5.  Regulation of CXCR2 expression and function by a disintegrin and metalloprotease-17 (ADAM17).

Authors:  Hemant K Mishra; Chunmei Long; Nooshin S Bahaie; Bruce Walcheck
Journal:  J Leukoc Biol       Date:  2014-11-20       Impact factor: 4.962

6.  Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17.

Authors:  Petra C Buchanan; Kristin L M Boylan; Bruce Walcheck; Rachel Heinze; Melissa A Geller; Peter A Argenta; Amy P N Skubitz
Journal:  J Biol Chem       Date:  2017-02-23       Impact factor: 5.157

7.  ADAM17 cleaves CD16b (FcγRIIIb) in human neutrophils.

Authors:  Yue Wang; Jianming Wu; Robert Newton; Nooshin S Bahaie; Chunmei Long; Bruce Walcheck
Journal:  Biochim Biophys Acta       Date:  2012-12-08

8.  NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17).

Authors:  Rizwan Romee; Bree Foley; Todd Lenvik; Yue Wang; Bin Zhang; Dave Ankarlo; Xianghua Luo; Sarah Cooley; Mike Verneris; Bruce Walcheck; Jeffrey Miller
Journal:  Blood       Date:  2013-03-13       Impact factor: 22.113

9.  Ectodomain shedding by ADAM17 (a disintegrin and metalloproteinase 17) in canine neutrophils.

Authors:  Kristin M Snyder; Camille A McAloney; Joshua S Montel; Jaime F Modiano; Bruce Walcheck
Journal:  Vet Immunol Immunopathol       Date:  2020-11-17       Impact factor: 2.046

10.  Molecular Descriptors in Modelling the Tumour Necrosis Factor-α Converting Enzyme Inhibition Activity of Novel Tartrate-Based Analogues.

Authors:  P Singh
Journal:  Indian J Pharm Sci       Date:  2013-01       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.